Have a personal or library account? Click to login
COVID-19 vaccines: Where do we stand? Cover
Open Access
|Jan 2021

References

  1. Sun P, Lu X, Xu C, Sun W, Pan B. Understanding of COVID-19 based on current evidence. J Med Virol 2020;92:548–551.
  2. C. H, Y. W, X. L, L. R, J. Z, Y. H. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet (London England) 2020;497–506:497–506.
  3. Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet (London England) 2020;395:507–513.
  4. Brian DA, Baric RS. Coronavirus genome structure and replication. Curr Top Microbiol Immunol 2005;287:1–30.
  5. Wrapp D, Wang N, K. SC, J. AG, C. LH, Abiona O. Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. Sci (N Y NY) 2020;367:1260–1263.
  6. A. CW, Y. JP, M. AT, Wall A, A. TM, Veesler D. Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein. Cell 2020;181:281–292.e286.
  7. Sternberg A, Naujokat C. Structural features of coronavirus SARS-CoV-2 spike protein: Targets for vaccination. Life Sci 2020;257:118056.
  8. Sun J, Zhu A, Li H, Zheng K, Zhuang Z, Chen Z. Isolation of infectious SARS-CoV-2 from urine of a COVID-19 patient. Emerg Microbes Infect 2020;9:991–993.
  9. Zhu F, Li Y, Guan X, Hou L, Wang W, Li X. Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial. Lancet (London England) 2020;395:1845–1854.
  10. Pandey SC, Pande V, Sati D, Upreti S, Samant M. Vaccination strategies to combat novel corona virus SARS-CoV-2. Life Sci 2020;256:1179.
  11. Yu P, Qi F, Xu Y, Li F, Liu P, Liu J, et al. Age-related rhesus macaque models of COVID-19. Anim Model Exp Med 2020;3:93–97.
  12. Gao Q, Bao L, Mao H, Wang L, Xu K, Yang M, et al. Development of an inactivated vaccine candidate for SARS-CoV-2. Science (80- ) 2020;369:77–81.
  13. Mathew S, Faheem M, Hassain N, Benslimane F, Al Thani A, Zaraket H, et al. Platforms Exploited for SARS-CoV-2 Vaccine Development. Vaccines 2021;9(11).
  14. Zhang H, Penninger JM, Li Y, Zhong N, Slutsky AS. Angiotensin-converting enzyme 2 (ACE2) as a SARS-CoV-2 receptor: Molecular mechanisms and potential therapeutic target. Intensive Care Med 2020;46:586–590.
  15. Mercado NB, Zahn R, Wegmann F, Loos C, Chandrashekar A, Yu J, et al. Single-shot Ad26 vaccine protects against SARS-CoV-2 in rhesus macaques. Nature 2020;586:583– 588.
  16. Flingai S, Czerwonko M, Goodman J, Kudchodkar S, Muthumani K, Weiner D. Synthetic DNA Vaccines: Improved Vaccine Potency by Electroporation and Co-Delivered Genetic Adjuvants. Front Immunol 2013;4.
  17. Amanat F, Krammer F. SARS-CoV-2 Vaccines: Status Report. Immunity. 52 2020;583–589.
  18. Tu Y, Chien C, Yarmishyn A, Lin YY, Luo Y, Lin YT. A Review of SARS-CoV-2 and the Ongoing Clinical Trials. Int J Mol Sci 2020;21:2657.
  19. Jackson LA., Anderson E, Rouphael N, Roberts P, Makhene M, Coler R. An mRNA Vaccine against SARS-CoV-2 - Preliminary Report. New Engl J Med 2020;
  20. Dawood AA. Mutated COVID-19, May Foretells Mankind in a Great Risk in the Future. New Microbes New Infect 2020;35:100673.
  21. Korber B, Fischer WM, Gnanakaran S, Yoon, H. T, Heiler J, Abfalterer W, et al. Tracking changes in SARS-CoV-2 Spike: evidence that D614G increases infectivity of the COVID-19 virus. Cell 2020;
  22. Saha P, Banerjee, A.K., Tripathi PP, Srivastava AK, Ray U. A virus that has gone viral: amino acid mutation in S protein of Indian isolate of Coronavirus COVID-19 might impact receptor binding, and thus, infectivity. Biosci Rep 2020;40:BSR20201312.
  23. Becerra-Flores M, Cardozo T. SARS-CoV-2 viral spike G614 mutation exhibits higher case fatality rate. Int J Clin Pr 2020;(e13525).
  24. Li Q, Wu J, Nie J, Zhang L, Hao H, Liu S, et al. The Impact of Mutations in SARS-CoV-2 Spike on Viral Infectivity and Antigenicity. Cell 2020;182:1284–1294.
  25. Rauch S, Jasny E, Schmidt KE, Petsch B. New Vaccine Technologies to Combat Outbreak Situations. Front Immunol 2018;9:1963.
  26. Kaur SP, Gupta V. COVID-19 Vaccine: A comprehensive status report. Virus Res 2020;288:198114.
  27. van Riel D, DeWit E. Next-generation vaccine platforms for COVID-19. Nat Mater 2020;19:810–812.
  28. Armengol G, Ruiz LM, Orduz S. The injection of plasmid DNA in mouse muscle results in lifelong persistence of DNA, gene expression, and humoral response. Mol Biotechnol 2004;27:109–118.
Language: English
Page range: 4 - 7
Published on: Jan 22, 2021
Published by: European Biotechnology Thematic Network Association
In partnership with: Paradigm Publishing Services
Publication frequency: 4 issues per year

© 2021 Pinar Tulay, Mahmut Cerkez Ergoren, Munis Dundar, published by European Biotechnology Thematic Network Association
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.